Our 2017 Finalists

We’d like to congratulate all our finalists for their outstanding contribution to innovation, improving the lives of patients and supporting HCPs.

Most Valuable Patient Initiative or Service

The finalists of this award are innovative projects designed to deliver tangible patient improvements both in the long and short term. Demonstrating real understanding for the patient requirements prior to implementation, these finalists have been managed to an outstanding level and have made an exceptionally positive impact on their intended customer.

WINNER
EUROPEAN FINALIST

Takeda with Red Door Unlimited: #FlyWithIBD

more info watch video

Approximately 32 million people live with inflammatory bowel diseases (IBD) or irritable bowel syndrome (IBS) in Europe. Air travel can be stressful for those living with IBD or IBS, mainly because limited inflight meal options can exacerbate their condition. Many of these patients have restrictive dietary requirements and failure to comply with them may lead to serious relapses of their disease, which can severely impact their health.

Inspired by the experiences of a colleague with IBD on a business trip to Japan, the communications team at Takeda Europe and Canada decided to try and make a difference for people travelling with IBD and IBS. Their mission was to raise awareness of the challenges faced by travellers with IBD/IBS and encourage airlines to provide greater choice & detail on ingredients of foods offered on flights, to create a more positive experience for travellers living with IBD/IBS. This video shows Sarah Heidrich, Takeda employee living with IBD, explaining how the #FlyWithIBD campaign came about: www.youtube.com/watch?v=UJSm9LMim1E

NORTH AMERICAN FINALIST

BMS with Bridgeable: Universal Patient Language (UPL)

more info watch video

The Universal Patient Language (UPL) is an organizational capability and set of practical resources that help communicate complex topics to patients. Developed by Bristol-Myers Squibb (BMS), the story of the UPL presents a unique approach to patient experience. By focusing on patient communication, a tangible pillar of patient experience where BMS has specific, high potential impact, the UPL has become a practical vehicle through which BMS creates better patient experience. The UPL has been applied to Bristol-Myers Squibb patient communications in every single disease state where the company has a product in market. The redesigned UPL deliverables include a wide variety of outputs, such as drug safety information, branded messaging, disease state education, clinical trial recruitment, and even call center interactions. In developing these outputs, Bristol-Myers Squibb has engaged with over 150 patients and caregivers, and over 100 healthcare providers, patient advocacy group representatives, communication experts, and other external stakeholders.

Finally, in 2016, Bristol-Myers Squibb launched the UPL an open-source capability, sharing it with anyone who is interested in working on patient communications. The first UPL resources and case studies are now publicly available on www.upl.org. The hope is that if all industry players — from hospital systems to advocacy groups to clinicians to pharma — adopt a set of universal standards in patient communications, patients’ overall healthcare experiences will be improved.

EUROPEAN FINALIST

Takeda with Lundbeck, Mcann Humancare and Klick Health: Lighter Blue

more info

More information coming soon…

NORTH AMERICAN FINALIST

Janssen: Patient Voice in Trial Design

more info watch video

Janssen’s “Patient Voice in Trial Design” initiative answers a critical need for clinical trials all over the world: engaging patients in the design and implementation of trials. This is necessary to not only improve enrollment and retention, but also to form a trusted and long-term relationship with patients, who are the ultimate healthcare stakeholders. Today, the cost of developing a new drug continues to rise; it takes $2.6 billion and more than 10 years to gain market approval for a new drug. Clinical trials are a factor in this timeframe as close to 80% of clinical trials experience delays, with each extra day costing a trial sponsor up to $8 million. Enrollment and retention are prime causes for delay. Whereas pharmaceutical companies perform extensive market research prior to a product’s market launch, little has often been done in seeking insights from patients when designing a trial. Yet these insights are invaluable in helping the sponsor understand perceived hurdles for study enrollment, as well as how to make a trial protocol meaningful for participation and how to ensure patients remain motivated and engaged throughout the study.

With its “Patient Voice in Trial Design” program Janssen intends to bridge this critical gap by creating the capability to seek and incorporate direct patient insights into trial design and operational planning.

EUROPEAN FINALIST

Takeda with Ketchum Inc: IBD Unmasked

more info watch video

IBD Unmasked is a first-of-its-kind global initiative designed to highlight both the daily battles and the remarkable strength of the unsung Super Heroes of patients living with IBD. IBD Unmasked features a team of IBD Super Heroes – The Unbeatables – and a graphic novel developed through a unique collaboration with Marvel Custom Solutions and the input of an international panel of patients living with IBD. Takeda is the first pharmaceutical company to partner with Marvel Custom Solutions on a disease awareness campaign raising awareness of health conditions.

NORTH AMERICAN FINALIST

UCB: Experts-by-Experience Panel

more info watch video

The Experts-by-Experience panel allows patients to engage with teams at UCB on equal footing. Our use of the term ‘Experts-by-Experience’ recognizes the person living with a condition as an equal who brings their own type of expertise to the table, rather than as a passive receiver of care.

This initiative permits UCB employees from across the company, for example in operations, safety, marketing, clinical, and medical affairs to co-create innovative solutions with patients for patients. A solution is a product or service (whole or component) provided to patients and/or other stakeholders in the health ecosystem.

EUROPEAN FINALIST

Janssen: Man Marking

more info watch video

Deine Manndeckung is a disease awareness campaign run in Germany, designed to raise awareness about early detection of prostate cancer.

Prostate cancer is the most prevalent cancer among men over the age of 45 in Germany, with 63,700 cases reported every year.

The Janssen team decided that the best way to connect with men over the age of 45 is through what they are most passionate about - football or handball. The campaign was run with the support of 16 top regional football clubs, including several in the professional football league Bundesliga, and was launched at many of their season open days.

The collaborative campaign, run by Janssen and supported by its partners – including sports clubs, payers, clinics, and urologists – collectively reached more than 260,000 people through various sports events across the country. Media coverage of the campaign has received 13.7 million views to date.

NORTH AMERICAN FINALIST

GlaxoSmithKline with CK Aspire: Domiciliary Team for the Salford Lung Study

more info

The Domiciliary Research Team piloted and launched by CK Aspire Ltd in June 2013 have pioneered a service to help facilitate pragmatic randomised controlled trials (pRCT) conducted in a real-world setting, that reflects clinical practice and the environment in which people live. Mobile recruitment can add value, through to improving subject retention, project flexibility and adaptability across the clinical trial setting and in patient homes. As industry is moving towards a ‘patient centric’ approach the ability for Research Organisations to provide novel solutions to access and engage hard to reach groups is becoming increasingly important. In-home clinical trials have faster enrolment rates and higher retention and compliance rates, and overall drug development cycle time metrics decrease. The domiciliary model can be adapted to most projects, the service can be resourced to a study that is having difficulty recruiting. A mobile team can learn the study protocol and procedures and adapt working practices across various community settings in the real world. Ultimately, medical products and devices are used in the home setting, so researching them in a real-world environment or community setting can be invaluable. For those who are suitable mobile services can be used as a rescue measure to alleviate increasing cost or delays in the course of the research project.

EUROPEAN FINALIST

LEO Innovation Lab: TREAT

more info watch video

TREAT is a nutrition coaching service dedicated to help people with inflammatory conditions. Following a rigorous scientific framework rooted in behaviour change theory, the service guides people through an 8-week individualised programme to help them understand, try and adopt anti-inflammatory principles into their diet.

TREAT has been incubated by LEO Innovation Lab, an independent unit of LEO Pharma dedicated to building solutions that improve the lives of people living with skin conditions.

NORTH AMERICAN FINALIST

Nektar Therapeutics with HealthiVibe: The Summit: Rising Together with Patients

more info watch video

Together, Nektar Therapeutics and HealthiVibe utilized a variety of approaches in support of a phase 3 study to infuse the patient perspective and focus on patient needs to improve the overall study execution. Working closely with patients to gather insights about what works and doesn’t work in all aspects of the study, HealthiVibe and Nektar utilized innovative methods of patient engagement that provided real-world approaches to improve the overall study from start to finish always considering the patient experience.

EUROPEAN FINALIST

Novartis: "Ask your Dermatologist"

more info watch video

Novartis conducted the largest global psoriasis patient survey to date. It set out to collect important data that would define the impact of psoriasis on their daily lives and assess what clear skin really means to them. The responses from nearly 9,000 psoriasis patients across 31 countries revealed some startling statistics.

  • 90% experienced negative feelings associated with psoriasis
  • 54% feel psoriasis has adversely affected their professional life
  • 50% avoid having sex or intimate relationships
NORTH AMERICAN FINALIST

AstraZeneca with DigitasLBi: LVNG With Lung Cancer

more info watch video

LVNG With Lung Cancer is a community of people living with lung cancer and their loved ones. Community members inspire each other to face each day with authenticity and hope. Brought to you by AstraZeneca

EUROPEAN FINALIST

Roche: Fight IPF

more info watch video

Roche designed and launched the innovative FightIPF campaign across Europe and Canada to raise awareness of the impact of IPF; an incurable lung disease that is in the shadows, aggressive, unpredictable.

Roche partnered with the IPF community to empower people living with the condition to strive to ‘fight today for more tomorrows’.

Inspired by the Philips Breathless Choir, Roche developed an integrated campaign, with a hero video sitting at the very core. The video, which has secured over 400K views, captured the children and grandchildren of people living with IPF together performing a surprise and emotional rendition of Rachel Platten’s Fight Song – a direct plea to their loved ones to seek help to manage their condition.

NORTH AMERICAN FINALIST

Janssen: Innovative Solutions in Pre-approval Access

more info watch video

If you or someone you love faced a life-threatening or serious illness, had exhausted standard treatment options, and did not qualify to participate in a clinical trial, it is important to have clear information on where to seek help. Increasingly, patients and their physicians may opt to seek access to investigational medicines not yet approved by health authorities such as the U.S. Food and Drug Administration. Janssen Research & Development, LLC (Janssen) understands the need for physicians of patients with limited options to request medicines prior to approval, and is committed to working diligently using a fair and timely decision-making framework. Creating a transparent, ethical and consistent process for pre-approval access requests is a top priority for the company. In May 2015, Johnson & Johnson announced a first-of-its-kind pilot partnership between Janssen and the Division of Medical Ethics at the New York University (NYU) School of Medicine to form the Compassionate Use Advisory Committee (CompAC). Comprised of external bioethical experts, physicians and patient representatives convened by NYU, the purpose of CompAC, a pilot program, is to ensure a fair, objective and ethical evaluation of single patient requests for investigational medicines. Having seen the success of the pilot, Johnson and Johnson is excited to implement across their portfolio for relevant assets. Companies, patient advocates, institutional review boards, and government officials have expressed interest in extending the CompAC model to other agents and settings.

EUROPEAN FINALIST

UCB: Spanish Health Ecosystem Solution Project

more info watch video

The Spanish Health Ecosystem Solution Project has been developed with an aim of evolving from treating patients to taking care of people, designing and implementing patient solutions that truly impact their lives.

UCB Pharma manufactures and commercializes Cimzia, an Anti-TNF indicated for Rheumatoid Arthritis, Spondiloarthritis and Psoriasic Arthritis, in Europe.

The objective with the Health Ecosystem Project is to link our Risk Sharing Agreements with a Patient Support Program to maximize the Cimzia patient experience during these first 12 weeks of onboarding, the most critical stage for new treatment for patients.

NORTH AMERICAN FINALIST

Abbott India: Vertigo Exercise Mobile App

more info watch video

Patient Education 3d HD 360 degree app for better treatment outcome with patients of Vertigo: Empowering HCP to ensure patience adherence and better outcomes

EUROPEAN FINALIST

Daiichi Sankyo Europe GmbH: Adherence Package

more info watch video

More information coming soon…

NORTH AMERICAN FINALIST

United Therapeutics Oncology: The Skivolo Project

more info

For children with neuroblastoma and those who care for them, the treatment journey can be long and confusing, full of hospitalizations, procedures, and drugs, even a new language. Parents need basic information. Kids just need a friend who understands what they’re going through. Working with oncology nurses, educators, and health literacy experts, we created informational materials that were easier to understand, and more important, designed to be shared between parents and kids: The Skivolo Project. The Skivolo project is a groundbreaking series of informational children’s books and digital projects that have filled a crucial need for hospitals and cancer centers, and are being translated into 5 languages.

COMMENDED
EUROPEAN FINALIST

AbbVie: Doctors Channel YouTube

more info watch video

Complex Medical Information is made Easy & Accessible by AbbVie's 'Doctors Channel on YouTube'. It provides educational health videos on a wide variety of medical conditions & diseases-directly from the experts. Senior physicians voluntarily joined the initiative to create short, simple and clear videos that explain symptoms, disease progression, treatment methods and provide links to further information. Hundreds of thousands of surfers have already obtained objective and reliable answers, information & directions prior to an office visit, saving valuable time during the actual doctor’s appointment.

NORTH AMERICAN FINALIST

Abbott India: Wifi Thyroid Clinics

more info watch video

Abbott has always been in the forefront of initiatives to spread awareness about thyroid disorders, improve access to diagnosis and help millions of Indians lead a better life. Wifi Thyroid Clinics” – Is an Effective and Measurable way for Patient awareness on thyroid disorders inside the doctor’s clinic. This initiative has helped convert “waiting time” in doctor’s chamber to “awareness building time” using internet less wifi technology and further helped Abbott India to move a step closer in their vision of Making India Thyroid Aware. The initiative was launched in 252 Endocrinologists clinics. The objective of launching at Endocrinologist clinics has been high inclinic waiting time and Endos getting large pool of patients with high risk of thyroid disorders. The initiative was launched during World Thyroid Day in the month of May and has reached out to 85000 patients in 6 month’s time with 330 view/download rate per clinic.

NORTH AMERICAN FINALIST

UCB: Right Start Nurse Program

more info watch video

For most patients, living with and self-managing a chronic condition requires a fair amount of knowledge, gentle care and, most of all, strong support. Now in its expansion phase, UCB’s CIMplicity® Right Start Nurse Program is a free, educational resource that provides exactly what new CIMZIA® patients need—with the right information, delivered at just the right time throughout their journey. Initially, 300-400 CIMZIA patients registered monthly, which has increased to 500+ monthly. Since inception, more than 45K calls were successfully made. Overall, the program received a 99% satisfaction rate, with Net Promoter Scores (NPS) of 67% likely to recommend the program and 54% likely to recommend speaking to a doctor about CIMZIA.

Most Valuable Pharma Collaboration

The finalists of this award are either a pharma-pharma or pharma-non-pharma initiative which clearly brings a new proposition to customers and/or healthcare systems, creates new value and redefines what is possible in our industry with a degree of lateral thinking.

EUROPEAN FINALIST

AbbVie: What happens when patients meet young talented designers

more info watch video

This project was based on the Pharma 3.0 business model- partnering with non-traditional partners to improve health-related outcomes, using an holistic approach. This pioneering innovative project was initiated following AbbVie’s patient centric approach. Following findings from patient journeys, interviews with HCP & Patients, market research and more, we gather lot observations and develop insights about the daily life struggles of the patients. AbbVie collaborate together with relevant partners as- Bezalel (Academy of arts & design), Patient Association Groups, HCPs, to develop innovative tailored solutions to address RA patients’ & Parkinson patients' unmet needs , in order to create a remarkable impact on their lives.

NORTH AMERICAN FINALIST

phactMI

more info watch video

phactMI™ is a collaboration of pharmaceutical company Medical Information (MI) departments that are dedicated to supporting healthcare professionals in their commitment to provide quality patient care.

At phactMI, we understand that healthcare professionals have a wide range of medical information needs, and we are supportive of the spectrum of drug information providers. phactMI.org is a unique portal that provides easy access the resources of Medical Information departments of phactMI member companies.

phactMI.org can help you access current, accurate, and scientific information, about drug interactions, stability/compatibility, and dosage and administration – sometimes including access to unpublished information that may not be available from our member pharmaceutical organizations.

WINNER
EUROPEAN FINALIST

AbbVie: Doctors Channel YouTube

more info watch video

Complex Medical Information is made Easy & Accessible by 'Doctors Channel on YouTube'. It provides educational health videos on a wide variety of medical conditions & diseases-directly from the experts. Senior physicians voluntarily joined the initiative to create short, simple and clear videos that explain symptoms, disease progression, treatment methods and provide links to further information. AbbVie’s vision and foresight underpins this major step toward answering patients' needs by bringing to life this online “go-to” resource. Thanks to the participation of major stakeholders, patients know they are accessing the best information available online.

NORTH AMERICAN FINALIST

The Critical Path Institute

more info

Critical Path Institute (C-Path), founded in 2005 in Tucson, Arizona, is an independent, nonprofit organization established with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the US Food and Drug Administration (FDA). C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established 12 global, public-private partnerships that currently include over 1,450 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. 

EUROPEAN FINALIST

LEO Innovation Lab with The Happiness Research Institute: PsoHappy

more info watch video

People living with psoriasis are up to 24% less happy than the average population. This is a significant gap and PsoHappy, the first happiness index for people living with psoriasis, is committed to documenting and addressing the well-being inequalities psoriasis creates.

PsoHappy will continue to document the levels of happiness and explore what makes good living for people with psoriasis, while also expanding the successful approach to other skin and chronic disease areas. Our aim is to build a coherent, strong strategy around happiness that can unite all the relevant stakeholders and people living with psoriasis in one strong voice.

NORTH AMERICAN FINALIST

"Inspiring Hope" Ideathon

more info watch video

Innovation through Collaboration: INC Research and the Center for Information and Study on Clinical Research Participation (CISCRP) worked in partnership to develop the "Inspiring Hope" Ideathon, a new crowdsolving competition designed to generate unique and effective ideas that raise awareness of clinical trials and study participation.

This ground breaking event, held on September 27-28, 2016 at District Hall in Boston, brought together industry leaders and patients along with advocacy groups and other stakeholders from multiple industries to address:

  • raising public awareness about the role that clinical research plays in our society
  • building more momentum to increase personal, long-term and ongoing participation in clinical studies
  • stimulating more active engagement within the clinical research community, particularly those who seek alternative health care options
  • creating higher levels of recognition and appreciation for clinical trial volunteers

In a competition that inspired nearly 70 entries from around the world, 14 ideas were then shortlisted for their potential to help address the critical need to increase awareness of clinical trial participation among patients, healthcare professionals and the general public.

As a result of the live competition and a tremendous amount of momentum, the winning team, in collaboration with INC Research and CISCRP, now focuses on progressing the idea into a viable solution. Since the event, INC and CISCRP have held a kick off meeting with the winning team, which has already started making their idea a reality. Subsequent progress meetings are planned for the remainder of this year and updates will be presented at patient-focused events throughout next year.

EUROPEAN FINALIST

Novartis: Europe Patient Innovation Summit

more info watch video

The European Patient Innovation Summit brought together over 130 patient advocacy groups from across 22 European countries to discuss how technology is revolutionizing life for patients and patient groups alike. With 8 different disease communities represented (ankylosing spondylitis, asthma, heart failure, migraine, multiple sclerosis, psoriasis and psoriatic arthritis, rare autoinflammatory diseases; retina) the Summit created a platform for knowledge exchange and best practice sharing through an innovative mix of presentations, panel discussion and Q&A sessions, workshops, and disease-community forums. The momentum gained during the meeting is being maintained and plans for the next event are already well under way.

NORTH AMERICAN FINALIST

The Clinical Study Data Request Consortium

more info watch video

Very often, patient level data are isolated and scattered among research sponsors, seldom being shared. Because of this, clinical research, with all its challenges, is often duplicated and can potentially miss signals that may only become clear when data pools are combined. The Clinical Study Data Request (www.clinicalstudydatarequest.com) launched in 2014, now has 13 member companies who represent a consortium of industry leaders in the data sharing community. Through a common mission, they are inspired to drive value for patients through scientific and medical innovation by facilitating the responsible sharing of patient-level data from clinical studies.

The aim is to realize a broad, independent solution to allow access to data from clinical studies conducted by multiple companies and organisations, encouraging openness and transparency. The members of ClinicalStudyDataRequest.com set the bar for themselves to be the researcher-preferred platform for accessing high-quality patient-level data. This consortium offers researchers the most vast and broadest therapeutic variety of any data access platforms currently available. While doing so, they also uniquely balance the priority of data access and data utility with industry-leading principles and practices to ensure protection of patient privacy, scientific merit, and maintain a focus on patient value in the resulting researcher.

In alignment with the five guiding principles established by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) for the responsible sharing of clinical study data, the member companies have committed to the following: enhancing data sharing with researchers; enhancing public access to clinical study information; sharing results with patients who participate in clinical studies; certifying procedures for sharing clinical study information; and reaffirming commitments to publish clinical study results.

To that end, ClinicalStudyDataRequest.com has put real energy and careful thought into meeting the challenges of protecting patient confidentiality, applying the practicalities of anonymizing data and sharing data via secure access systems, and by design of their independent review process, ensuring that data is used for valid scientific verification or innovation, by qualified research teams, with potential benefit to patients. The site is the broadest one of its kind, with the highest sponsor commitment—including an independent review panel (managed by The Wellcome Trust) to ensure trust and accuracy.

EUROPEAN FINALIST

aparito: mHealth to capture meaningful patient outcomes in rare diseases

more info watch video

With the continuing pressures on NHS resources, clinicians time and increased costs on transportation, the ability to remotely monitor a patient with a progressive disease is a distinct advantage. Patients would not have to struggle to get to the hospital unless absolutely required and the consultant can review data from the APP and the wearable in an environment with less time constraints than at a patient appointment. The consultant can also be more aware of the progression of the disease by evaluating the data before a patient attends clinic therefore ensuring time at the clinic is not wasted. From the pharma industry perspective, accurate recording of patient progression on treatment can enable clinicians to gauge the benefits of the treatment and report findings appropriately in peer reviewed journals or international symposia.

NORTH AMERICAN FINALIST

Takeda Oncology, Multiple Myeloma Research Foundation and CURE Media Group: Moving Mountains for Multiple Myeloma Team

more info watch video

Moving Mountains for Multiple Myeloma is a collaboration between CURE Media Group, Takeda Oncology and the Multiple Myeloma Research Foundation (MMRF) to raise awareness and funds for multiple myeloma research. Multiple myeloma is an incurable blood cancer that gives patients less than a 50 percent chance of survival beyond five years, according to the National Cancer Institute. The program, launched in September 2015, brings together multiple myeloma patients, family members, doctors and supporters to raise funds, inspire hope and spread awareness of the disease. Since its launch, Moving Mountains for Multiple Myeloma has led teams of fearless climbers on hikes to Mount Kilimanjaro, the Grand Canyon and Machu Picchu. To date, the program has raised a total of nearly $500,000 for multiple myeloma research.

EUROPEAN FINALIST

The Synergist: Patient Focused Medicines Development Initiative

more info watch video

Medicines are developed to improve the lives of patients. Serving patients in the best way possible requires a deep understanding of their needs and priorities, which can be gained only through direct, sustained and constructive interactions with patients. Health stakeholders agree that broadening patient engagement is key to improving drug development and providing solutions that achieve both clinical and patient-desired outcomes. What is needed now is a consistent approach to patient engagement, through development and implementation of an efficient, measurable and reliable meta-framework that involves patients as partners. By partnering with patients to design and develop new solutions, we can co-create methods to help them achieve and maintain their health goals. The Patient Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition whose activities are funded by member organisations. It is an open non-profit partnership based on expertise and commitment toward better and meaningful patient engagement inside and outside of member organisations.

NORTH AMERICAN FINALIST

Bayer & the Hemophilia Advocacy Advisors Board: A Model of Authentic Partnership

more info watch video

While patient advocates have long been an important part of the medical landscape, manufacturers have traditionally distanced themselves from engaging with these crucial stakeholders. Bayer was keen to shift this phenomenon and create an authentic engagement opportunity with the world’s most recognized patient advocates, so together they could identify and tackle the most critical issues and concerns faced by those living with hemophilia. The challenge was to do so in a credible way that protected the patient and was not perceived as being self-serving. It was also essential that this activity was supportable from a business perspective, while delivering tangible results.

And the results have been exceptional; with the creation of Hemophilia Excellence by Bayer, a comprehensive portfolio of support programs and resources for patients, caregivers and healthcare professionals, and the establishment of the Hemophilia Advocacy Advisors Board (HAAB), an advisory body comprised of top patient advocates from across the globe, this partnership is set to address the unmet needs in the bleeding disorders community.

Unique in the industry, this partnership is raising the standard of care across the globe and is a superb example of how authentic engagement can exist – and thrive – despite today’s complex healthcare environment. The HAAB provides expert guidance and support to help the hemophilia community advocate for itself in this rapidly changing environment, while keeping a close eye on the healthcare landscape to ensure that the standard of care is continually addressed. One of the most notable outputs of this partnership is the annual Global Haemophilia Advocacy Leadership Summit, which completed its fifth year in January in Amsterdam, The Netherlands. The Summit is a platform where advocates from around the world can identify and focus on issues affecting them and take part in trainings to implement change within their hemophilia communities.

Following a think tank model has fostered a true dialogue between the hemophilia community and its industry partners that elevates collaboration to a new level, while making a real difference in patients’ lives.

Most Valuable HCP or Healthcare Initiative

The finalists of this award are innovative projects designed to deliver tangible working and healthcare improvements both in the long and short term. Demonstrating understanding of real health requirements prior to implementation, these winning projects have been managed to an outstanding level and have made an exceptionally positive impact on their intended customer.

EUROPEAN FINALIST

Takeda: In Their Shoes

more info watch video

Campaign mission: Create a corporate communications programme that goes beyond traditional methods to transport employees into the patient world, increasing their understanding of patient lives.

NORTH AMERICAN FINALIST

Eli Lilly with VMS BioMarketing: The Safe Injection Training Program

more info watch video

The Safe Injection Training Program developed by Eli Lilly and Company and executed in conjunction with VMS BioMarketing was designed to significantly enhance the quality of education for HCPs caring for people with diabetes in a variety of institutional settings, large or small, whether they are transitioning between injection methods, piloting new methods, or training discharge staff to help patients self-manage their diabetes. Through partnering with facilities, anywhere from 10 to several thousand patient care staff—RNs, LPNs, PAs, MAs, RPhs, and PharmDs—are trained by a Lilly-contracted Nurse Educator to properly use a vial/syringe or a Lilly prefilled insulin pen for inpatient therapy or to prepare patients for discharge. Programs are presented in a variety of care settings including hospitals, long-term care facilities, pharmacies, or healthcare systems.

Whether they are administering insulin by vial and syringe or by an insulin pen, even veteran HCPs may benefit from training in best practices for insulin injection, the latest guidelines for storage, and current information on safety issues. Since 2008, over 100,000 HCPs have been trained. In a formal survey of customers, 98% felt the information learned in the program will improve safety practices for syringe or pen use at the facility.

EUROPEAN FINALIST

UCB: China HCP-Facing WeChat Project

more info watch video

In China, the traditional communication between HCPs and Pharma are brief face-to-face visits or meetings which result in low effectiveness (time consuming and high cost for transportation) and generalized content that is not tailored to HCPs’ needs.

UCB sought to facilitate higher effectiveness, as well as more immediate and audience-centric communication, for millions of HCPs in China via a free app platform that enabled HCPs to learn more about UCB solutions in related therapeutic areas. WeChat is an instant messaging service developed in 2011 by Tencent in China, and is now a leading social media platform and “go-to” information resource. It is one of the largest standalone messaging apps by monthly active users, with over a billion created accounts, 700 million active users—and more than 70 million outside of China. Meanwhile, on average, HCPs spent 23.7 hours (2015 survey) on internet for information every week and more than 90% HCPs in big cities use WeChat frequently. To facilitate better communication between HCPs and Pharma, it made sense to use a popular, accessible platform such as WeChat which is a well adopted platform with no additional training required for immediate use.

NORTH AMERICAN FINALIST

Allergan with Complete HealthVizion: IBSCounSEL.com

more info watch video

IBS affects approximately 11% of the world’s population – 35 million people in the US alone! It has a drastic physical and emotional impact; 38% of those in the tertiary setting have contemplated suicide. Despite being one of the most commonly encountered disorders in primary care and gastroenterology, IBS has historically been viewed as benign, often disregarded as unimportant or not a legitimate disease. Internet searches of “IBS” yield over 42 million websites but these vary in quality and accuracy, and all share a lack of clear, clinically implementable information that healthcare professionals (HCPs) can trust. Consequently, many HCPs remain poorly informed; their misconceptions and lack of awareness can leave patients feeling stigmatized and suffering for years without a formal diagnosis or symptom relief.

With a firm commitment to improve the lives of people living with IBS, Allergan and Complete HealthVizion established a multidisciplinary expert group of gastroenterologists, primary care physicians, nurse practitioners, physician assistants, and patient advocates – The IBS CounSEL. Its mission is to provide Support, Education, and Leadership to achieve excellence in the care of people with IBS. This is the first and, to date, only multidisciplinary HCP group of its kind dedicated to improving IBS care.

A disease-awareness program was initiated to provide compelling and clinically relevant information to positively change HCP behaviors and improve the understanding, diagnosis, and management of IBS in day-to-day practice – IBSCounSEL.com was born! To date, IBSCounSEL.com has been accessed over 1500 times by over 900 unique visitors.

EUROPEAN FINALIST

GlaxoSmithKline with Vertic: Singapore Asthma 90 Second Speed Course

more info

Only 18% of Singapore asthma patients are controlled, while 56% of doctors believe them to be controlled.

Our task was to get this important message across to HCPs at Singapore polyclinics and provide them with the tools to uncover their patients’ lack of control. This audience is extremely time-poor and has less affinity with their patients compared to GPs or specialists who see the same patient regularly.

We needed to fit in with the HCP’s busy lives, convey the facts and tell the patients’ story in an interesting, compelling manner.

To differentiate ourselves from the usual long-form educational content HCPs are exposed to, we built our solution around brevity – making its low time-impact a key selling point. We developed the Singapore Asthma 90 Second Speed Course, a course delivered to HCP’s smartphones via a link sent by SMS during their morning commute (Singapore is a market where the use of public transport is prevalent at all levels of society).

NORTH AMERICAN FINALIST

Abbott India: In-clinic Scientific Detailing in Virtual Reality

more info watch video

VIRTUAL REALITY APP – GOOGLE CARDBOARD: Frugal innovation for immersive, differentiated experience (First in Industry Virtual Reality experience for scientific detailing to HCP via all medical reps)

WINNER
EUROPEAN FINALIST

Boehringer Ingelheim: The Angels Initiative

more info watch video

Every 30 minutes a stroke patient that could have been saved dies or is left permanently disabled because they are treated in the wrong hospital. In fact only about 1/3 stroke patients in Europe have access to organised stroke care.

The Angels Initiative was designed to change that by focussing on two clearly defined goals:

  1. We need to establish MORE stroke ready hospitals.
  2. We need to help all existing stroke centres and stroke ready hospitals get BETTER at treating acute stroke patients.

Our aim is to save 100,000 lives by creating a community of 1,500 stroke ready hospitals all working together every day to improve their stroke care. We aim to achieve this by May 2019.

NORTH AMERICAN FINALIST

Shire with Snow Companies: Patient Ambassador Stories to HCP Audiences

more info

Including Patient Ambassador Stories in HCP Audience programs is a novel way to raise awareness of Binge Eating Disorder (B.E.D.) in the healthcare community. Patient Stories bring a face and a name to the disorder and show the real impact B.E.D. has on everyday lives. Stories encourage open communication between healthcare professionals and patients which can help identify patients and lead to higher diagnosis rates. By incorporating stories, companies can bring about positive and meaningful change in the healthcare industry and further educate and assist the community in awareness, recognition, and adoption.

EUROPEAN FINALIST

Novartis with Boomerang: ViaOpta Simulator

more info watch video

Over a quarter billion visually impaired patients are treated each year. Until now physicians have not been able to truly visualize the real world implications these patients face.

Better treatment begins with better understanding - Not only the physical, but also the emotional frustration of the patient.

With the ViaOpta Simulator app physicians can view life through the lens of a patient.

Virtually replicated syndromes and corresponding scientific descriptions come together to form a portable augmented reality experience. Bringing physicians and patients closer together by allowing the physicians to walk in the patients shoes and continue a dialog that treats beyond the conventional pill.

ViaOpta Vision simulator app - Designed specifically for healthcare professionals, your first person look at living with a visual impairment.

EUROPEAN FINALIST

Lundbeck with Complete HealthVizion: ReTHINCing the role of cognition in depression

more info watch video

More information coming soon…

Customer Innovator Award

The finalists of this award is a person or team who have determined the needs of their customer, and created a relevant approach irrespective of traditional methods. They have an exceptional aptitude for having or sourcing innovative ideas as well as executing them effectively. The finalists exhibit the qualities of a true innovator, who strives for patient value, influences others and provides useful learning and examples for others in the industry.

Finalist Headshot
EUROPEAN FINALIST

Bridha Sridhar, UCB, DRIVE™ Parkinson's Disease Treatment Drivers

more info watch video

Due to a high level of uncertainty with their medications, patients with Parkinson’s Disease often make ambiguous trade-offs. Switching to other treatment choices results in a 40-50% drop-off rate after first month of treatment up through the third month – but why, and what are the triggers? Lack of any objective measure means subjective feelings heavily moderate decision making.

To address the real patient needs, we sought research methodologies that go beyond focus groups and interviews, which mostly deal with the conscious and rational responses. Innovative approaches that are designed to minimize bias in research settings were deployed.

The UCB DRIVETM PD Research team is a cross-practice, cross-region and cross-mission initiative aimed at understanding subconscious drivers in the Parkinson’s patient journey, starting with the premise that around 80% of drivers are subconscious.

Finalist Headshot
NORTH AMERICAN FINALIST

Akshat Aiyer, Abbott India

more info watch video

More information coming soon…

Finalist Headshot
WINNER
EUROPEAN FINALIST

Kristian Hart-Hansen, LEO Innovation Lab, LEO Pharma

more info watch video

LEO Innovation Lab is one of a kind, ambitious initiative designed to improve the lives of people living with skin conditions by adopting user-centric principles and disrupting the usual approaches of pharma.

In less than 18 months since he established the Lab, Kristian Hart-Hansen, its co-founder and CEO, has championed more than 35 concepts and prototypes, out of which 8 are already available to patients in UK, Canada and Denmark. He has built a multi-disciplinary team of 40 designers, software engineers, business specialists, growth hackers, anthropologists that are using agile development principles to develop and launch at pace solutions that are underpinned by technology and data to improve the lives of living with skin conditions.

Finalist Headshot
NORTH AMERICAN FINALIST

Kathy Cole, PMG Research

more info watch video

With time and costs continuing to be systemic, unstainable issues for our industry as a whole, Kathy Cole made a decision to leverage her knowledge, expertise and passion to do her part in reversing the trend. Her leadership in developing what is proving to be a high value process, Data-Driven Feasibility leads to predictable outcomes and has impacted the PMG business in a short period of time with expected long-term value to increase exponentially. Applied to the larger site enterprise and industry, it is plausible to expect a significant paradigm shift in the years ahead that reduces time and cost simply through effective and reliable analysis used to ensure the right trials are placed at the right sites with the right providers.

Finalist Headshot
EUROPEAN FINALIST

David Aubert, Psoriasis treatment beyond the pill, Philips BlueControl

more info watch video

New blue light therapy with Philips BlueControl – a big step for psoriasis treatment and patients’ lives.

Convenience is a key factor when consumers all over the world choose services, products and suppliers. This trend also affects the medical world. In particular, patients with chronic diseases are looking for treatments that interfere less with their everyday lives and make them feel less like a patient.

International studies conclude that 75% of psoriasis patients are dissatisfied with their treatment. The frequent application of ointments is perceived to be inconvenient and time-consuming, limiting patients in their daily activities. The treatment compliance is low.

The need for a new treatment paradigm taking the practical and emotional impact the treatment poses on the patients more into account is obvious. In other words, treatments need a “usability upgrade” – it needs to be easier to integrate treatments into the patients’ daily lives and reduce the worries about side effects.

With the introduction of the blue light phototherapy device Philips BlueControl, we have proven that treatments that are gentle, convenient and effective noticeably improve the compliance rate. Our recent clinical study concludes that 98% of patients were compliant in following the blue light treatment recommendations over the trial period of four months.

As Philips BlueControl is effective by using visible blue light only, no UV radiation risks are associated. Philips BlueControl is the world’s first wearable UV-free blue LED light medical device to treat plaque psoriasis at home.

Finalist Headshot
NORTH AMERICAN FINALIST

Peter Stueckemann, UCB

more info

The CIMplicity® Home Health Program, launched in 2008, is the only one in its category that offers in-home support. It is also the only patient-centered program in its category that can quantify patient value: A 10% greater drug persistency over eight years; 20% greater compliance, also sustained over eight years; 50% fewer hospitalizations; and subsequently reduced payer costs of $4k-$10k per patient. Since the program’s inception, CIMZIA has consistently held a net promoter score of 67—unprecedented for a drug in the Crohn’s disease category.

Finalist Headshot
NORTH AMERICAN FINALIST

Nicki Norris, Symphony Clinical Research

more info watch video

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Christine Grogan, Acelity

more info

More information coming soon…

Lifetime Achievement Award

Finalist Headshot
EUROPEAN FINALIST

Professor Richard Barker, Director, CASMI

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Len Schleiffer, Chief Executive, Regeneron

more info

Leonard S. Schleifer, MD, PhD, founded Regeneron in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

Here a 3 minute clip about Len’s motivation for leading Regeneron here https://www.regeneron.com/leadership

Here is a video of Len explaining why the pharma industry doesn’t actually put patient’s first http://video.cnbc.com/gallery/?video=3000582820

Finalist Headshot
WINNER
EUROPEAN FINALIST

Richard Bergström, Director-General, EFPIA

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Freda Lewis-Hall, CMO, Pfizer

more info

As Pfizer's Chief Medical Officer, Freda Lewis-Hall leads Pfizer Medical, the division of the company responsible for the safe, effective and appropriate use of Pfizer medicines and vaccines around the world. Before joining Pfizer in 2009, Freda held senior leadership positions in medical affairs and new product development with Vertex, Bristol-Myers Squibb, Pharmacia and Lilly. Prior to joining the biopharmaceutical industry, she served as vice chairperson and associate professor of the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. Trained as a psychiatrist, Freda launched her medical career in frontline patient care and became well known for her work on the effects of mental illness on families and communities, and on issues of health care disparities. She is a Distinguished Fellow of the American Psychiatric Association.

In 2010, Freda was appointed by the Obama Administration to the inaugural Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI), and in 2012 she was appointed chair of the Cures Acceleration Network Review Board and a member of the National Center for Advancing Translational Sciences (NCATS) Advisory Council of the National Institutes of Health. She also serves on the Executive Committee of the Clinical Trials Transformation Initiative and on numerous other boards, including those of Harvard Medical School, Save the Children, Tenet Healthcare Corporation, and The Institute of Medicine’s Forum on Drug Discovery, Development, and Translation.

She shares health and medical information at GetHealthyStayHealthy.com

Here is Freda talking at TEDMED https://youtu.be/wY8I-2rDgNE

Finalist Headshot
EUROPEAN FINALIST

Dr Dominique Limet, CEO, ViiV Healthcare

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Ken Getz, CISCRP & Tufts

more info

Kenneth A. Getz is the Founder and Chairman of The Center for Information and Study on Clinical Research Participation (CISCRP), a nonprofit organization that he created to educate and raise public awareness of the clinical research enterprise, the Director of Sponsored Research Programs and an Associate Professor at the Center for the Study of Drug Development, Tufts University School of Medicine, where he studies R&D management and operating models, investigative site, outsourcing, and study volunteer trends and policies. Ken is also the Founder and former owner of CenterWatch, a trusted online source for detailed information about active clinical trials that can be accessed by patients and their advocates.

Mr. Getz is well known and highly respected throughout the pharmaceutical, research, and academic industries and has extensive experience measuring public and patient attitudes, perceptions, and experiences with all aspects of the clinical research process. He has worked tirelessly to find new and better ways to improve patient experiences with clinical research and transform public perception about clinical trial participation.

Mr. Getz is also a distinguished speaker at conferences, symposia, universities, and corporations, and has published more than 200 articles and chapters in peer-review journals, books, and in the trade press. He is the author of two nationally recognized books for patients, their families, and advocates titled, “Informed Consent: A Guide to the Risks and Benefits of Volunteering for Clinical Trials” and “The Gift of Participation.” Mr. Getz has also been the recipient of several awards for innovation and scholarship, such as the 2006 “Innovator in Clinical Research” award from the Association of Clinical Research Professionals (ACRP), a 2011 Lifetime Achievement award from the Institute of International Research, and a 2015 DIA Fellow inductee. Mr. Getz has held a number of board appointments in the private and public sectors, including serving on the Institute of Medicine’s Clinical Research Roundtable, the DIA Foundation, ACRP's Future Trends Committee, the Board of Directors of the DIA Foundation, the Consortium to Examine Clinical Research Ethicist Johns Hopkins, and the Clinical Trials Transformation Initiative (CTTI).

In 2007, Mr. Getz was named was named one of the 100 most inspiring individuals in the life sciences. Most recently, Mr. Getz and CISCRP, joined forces with INC Research to hold the first ever “Inspiring Hope” Ideathon, where more than 70 ideas where submitted for a crowd-sourcing competition to find new, innovative solutions for increasing clinical research awareness.

Finalist Headshot
EUROPEAN FINALIST

Sir Andrew Witty, CEO, GlaxoSmithKline

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Joaquin Duato, CEO, Johnson & Johnson Pharmaceuticals

more info

Joaquin Duato is a globally experienced, values-driven healthcare business leader and currently the Executive Vice President and Worldwide Chairman, Pharmaceuticals, at Johnson & Johnson, the world’s premiere healthcare company and fifth largest pharmaceutical business. He is a respected industry leader and is the Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). In recognition of his thought leadership, he was recently appointed to the Board of the CEO Roundtable on Cancer.

Joaquin played an instrumental role in leading the dramatic turnaround of the Johnson & Johnson pharmaceuticals business. A 27-year veteran of the Company, Joaquin was named Company Group Chairman of the Americas in 2009. He then continued leading the global transformation upon his appointment as Worldwide Chairman in 2011. With a proven track record of creating innovative commercial solutions and processes to support the Company’s cutting-edge medicines, he inspires employees to focus on transforming the lives of patients. The results are clear: with 16 new products launched since 2009 and 10 potential billion dollar medicines expected to be filed before 2019, the Johnson & Johnson pharmaceuticals sector is poised to remain one of the fastest growing top 10 pharmaceutical companies globally.

As a dual citizen of Spain and the US, Joaquin brings a unique international perspective to his work. With a career spanning three countries and two regions, he appreciates the value of diversity of experiences and perspectives. He brings this to bear externally as an active Board member of the US Spain Council and internally as the Executive Sponsor of the African American Leadership Council. His commitment to nurturing a culture of diversity was recognized in 2015 when he was named one of America’s Top 10 Hispanic Business Leaders by Hispanic Career World.

He is a champion of improving access to both health literacy and education more broadly through his role as Board member of the international charity Save the Children. He has served on the International Advisory Board of ESADE. Ultimately, Joaquin approaches every day with a clear sense of purpose and urgency, inspired by the words of Dr. Paul Janssen, “the patients are waiting.”

Joaquin speaking about how the industry needs to focus more on innovation https://www.youtube.com/watch?v=EStlI_-3ZR0

Most Valuable Patient Initiative or Service

The finalists of this award are innovative projects designed to deliver tangible patient improvements both in the long and short term. Demonstrating real understanding for the patient requirements prior to implementation, these finalists have been managed to an outstanding level and have made an exceptionally positive impact on their intended customer.

WINNER
EUROPEAN FINALIST

Takeda with Red Door Unlimited: #FlyWithIBD

more info watch video

Approximately 32 million people live with inflammatory bowel diseases (IBD) or irritable bowel syndrome (IBS) in Europe. Air travel can be stressful for those living with IBD or IBS, mainly because limited inflight meal options can exacerbate their condition. Many of these patients have restrictive dietary requirements and failure to comply with them may lead to serious relapses of their disease, which can severely impact their health.

Inspired by the experiences of a colleague with IBD on a business trip to Japan, the communications team at Takeda Europe and Canada decided to try and make a difference for people travelling with IBD and IBS. Their mission was to raise awareness of the challenges faced by travellers with IBD/IBS and encourage airlines to provide greater choice & detail on ingredients of foods offered on flights, to create a more positive experience for travellers living with IBD/IBS. This video shows Sarah Heidrich, Takeda employee living with IBD, explaining how the #FlyWithIBD campaign came about: www.youtube.com/watch?v=UJSm9LMim1E

NORTH AMERICAN FINALIST

BMS with Bridgeable: Universal Patient Language (UPL)

more info watch video

The Universal Patient Language (UPL) is an organizational capability and set of practical resources that help communicate complex topics to patients. Developed by Bristol-Myers Squibb (BMS), the story of the UPL presents a unique approach to patient experience. By focusing on patient communication, a tangible pillar of patient experience where BMS has specific, high potential impact, the UPL has become a practical vehicle through which BMS creates better patient experience. The UPL has been applied to Bristol-Myers Squibb patient communications in every single disease state where the company has a product in market. The redesigned UPL deliverables include a wide variety of outputs, such as drug safety information, branded messaging, disease state education, clinical trial recruitment, and even call center interactions. In developing these outputs, Bristol-Myers Squibb has engaged with over 150 patients and caregivers, and over 100 healthcare providers, patient advocacy group representatives, communication experts, and other external stakeholders.

Finally, in 2016, Bristol-Myers Squibb launched the UPL an open-source capability, sharing it with anyone who is interested in working on patient communications. The first UPL resources and case studies are now publicly available on www.upl.org. The hope is that if all industry players — from hospital systems to advocacy groups to clinicians to pharma — adopt a set of universal standards in patient communications, patients’ overall healthcare experiences will be improved.

EUROPEAN FINALIST

Takeda with Lundbeck, Mcann Humancare and Klick Health: Lighter Blue

more info

More information coming soon…

NORTH AMERICAN FINALIST

Janssen: Patient Voice in Trial Design

more info watch video

Janssen’s “Patient Voice in Trial Design” initiative answers a critical need for clinical trials all over the world: engaging patients in the design and implementation of trials. This is necessary to not only improve enrollment and retention, but also to form a trusted and long-term relationship with patients, who are the ultimate healthcare stakeholders. Today, the cost of developing a new drug continues to rise; it takes $2.6 billion and more than 10 years to gain market approval for a new drug. Clinical trials are a factor in this timeframe as close to 80% of clinical trials experience delays, with each extra day costing a trial sponsor up to $8 million. Enrollment and retention are prime causes for delay. Whereas pharmaceutical companies perform extensive market research prior to a product’s market launch, little has often been done in seeking insights from patients when designing a trial. Yet these insights are invaluable in helping the sponsor understand perceived hurdles for study enrollment, as well as how to make a trial protocol meaningful for participation and how to ensure patients remain motivated and engaged throughout the study.

With its “Patient Voice in Trial Design” program Janssen intends to bridge this critical gap by creating the capability to seek and incorporate direct patient insights into trial design and operational planning.

EUROPEAN FINALIST

Takeda with Ketchum Inc: IBD Unmasked

more info watch video

IBD Unmasked is a first-of-its-kind global initiative designed to highlight both the daily battles and the remarkable strength of the unsung Super Heroes of patients living with IBD. IBD Unmasked features a team of IBD Super Heroes – The Unbeatables – and a graphic novel developed through a unique collaboration with Marvel Custom Solutions and the input of an international panel of patients living with IBD. Takeda is the first pharmaceutical company to partner with Marvel Custom Solutions on a disease awareness campaign raising awareness of health conditions.

NORTH AMERICAN FINALIST

UCB: Experts-by-Experience Panel

more info watch video

The Experts-by-Experience panel allows patients to engage with teams at UCB on equal footing. Our use of the term ‘Experts-by-Experience’ recognizes the person living with a condition as an equal who brings their own type of expertise to the table, rather than as a passive receiver of care.

This initiative permits UCB employees from across the company, for example in operations, safety, marketing, clinical, and medical affairs to co-create innovative solutions with patients for patients. A solution is a product or service (whole or component) provided to patients and/or other stakeholders in the health ecosystem.

EUROPEAN FINALIST

Janssen: Man Marking

more info watch video

Deine Manndeckung is a disease awareness campaign run in Germany, designed to raise awareness about early detection of prostate cancer.

Prostate cancer is the most prevalent cancer among men over the age of 45 in Germany, with 63,700 cases reported every year.

The Janssen team decided that the best way to connect with men over the age of 45 is through what they are most passionate about - football or handball. The campaign was run with the support of 16 top regional football clubs, including several in the professional football league Bundesliga, and was launched at many of their season open days.

The collaborative campaign, run by Janssen and supported by its partners – including sports clubs, payers, clinics, and urologists – collectively reached more than 260,000 people through various sports events across the country. Media coverage of the campaign has received 13.7 million views to date.

NORTH AMERICAN FINALIST

GlaxoSmithKline with CK Aspire: Domiciliary Team for the Salford Lung Study

more info

The Domiciliary Research Team piloted and launched by CK Aspire Ltd in June 2013 have pioneered a service to help facilitate pragmatic randomised controlled trials (pRCT) conducted in a real-world setting, that reflects clinical practice and the environment in which people live. Mobile recruitment can add value, through to improving subject retention, project flexibility and adaptability across the clinical trial setting and in patient homes. As industry is moving towards a ‘patient centric’ approach the ability for Research Organisations to provide novel solutions to access and engage hard to reach groups is becoming increasingly important. In-home clinical trials have faster enrolment rates and higher retention and compliance rates, and overall drug development cycle time metrics decrease. The domiciliary model can be adapted to most projects, the service can be resourced to a study that is having difficulty recruiting. A mobile team can learn the study protocol and procedures and adapt working practices across various community settings in the real world. Ultimately, medical products and devices are used in the home setting, so researching them in a real-world environment or community setting can be invaluable. For those who are suitable mobile services can be used as a rescue measure to alleviate increasing cost or delays in the course of the research project.

EUROPEAN FINALIST

LEO Innovation Lab: TREAT

more info watch video

TREAT is a nutrition coaching service dedicated to help people with inflammatory conditions. Following a rigorous scientific framework rooted in behaviour change theory, the service guides people through an 8-week individualised programme to help them understand, try and adopt anti-inflammatory principles into their diet.

TREAT has been incubated by LEO Innovation Lab, an independent unit of LEO Pharma dedicated to building solutions that improve the lives of people living with skin conditions.

NORTH AMERICAN FINALIST

Nektar Therapeutics with HealthiVibe: The Summit: Rising Together with Patients

more info watch video

Together, Nektar Therapeutics and HealthiVibe utilized a variety of approaches in support of a phase 3 study to infuse the patient perspective and focus on patient needs to improve the overall study execution. Working closely with patients to gather insights about what works and doesn’t work in all aspects of the study, HealthiVibe and Nektar utilized innovative methods of patient engagement that provided real-world approaches to improve the overall study from start to finish always considering the patient experience.

EUROPEAN FINALIST

Novartis: "Ask your Dermatologist"

more info watch video

Novartis conducted the largest global psoriasis patient survey to date. It set out to collect important data that would define the impact of psoriasis on their daily lives and assess what clear skin really means to them. The responses from nearly 9,000 psoriasis patients across 31 countries revealed some startling statistics.

  • 90% experienced negative feelings associated with psoriasis
  • 54% feel psoriasis has adversely affected their professional life
  • 50% avoid having sex or intimate relationships
NORTH AMERICAN FINALIST

AstraZeneca with DigitasLBi: LVNG With Lung Cancer

more info watch video

LVNG With Lung Cancer is a community of people living with lung cancer and their loved ones. Community members inspire each other to face each day with authenticity and hope. Brought to you by AstraZeneca

EUROPEAN FINALIST

Roche: Fight IPF

more info watch video

Roche designed and launched the innovative FightIPF campaign across Europe and Canada to raise awareness of the impact of IPF; an incurable lung disease that is in the shadows, aggressive, unpredictable.

Roche partnered with the IPF community to empower people living with the condition to strive to ‘fight today for more tomorrows’.

Inspired by the Philips Breathless Choir, Roche developed an integrated campaign, with a hero video sitting at the very core. The video, which has secured over 400K views, captured the children and grandchildren of people living with IPF together performing a surprise and emotional rendition of Rachel Platten’s Fight Song – a direct plea to their loved ones to seek help to manage their condition.

NORTH AMERICAN FINALIST

Janssen: Innovative Solutions in Pre-approval Access

more info watch video

If you or someone you love faced a life-threatening or serious illness, had exhausted standard treatment options, and did not qualify to participate in a clinical trial, it is important to have clear information on where to seek help. Increasingly, patients and their physicians may opt to seek access to investigational medicines not yet approved by health authorities such as the U.S. Food and Drug Administration. Janssen Research & Development, LLC (Janssen) understands the need for physicians of patients with limited options to request medicines prior to approval, and is committed to working diligently using a fair and timely decision-making framework. Creating a transparent, ethical and consistent process for pre-approval access requests is a top priority for the company. In May 2015, Johnson & Johnson announced a first-of-its-kind pilot partnership between Janssen and the Division of Medical Ethics at the New York University (NYU) School of Medicine to form the Compassionate Use Advisory Committee (CompAC). Comprised of external bioethical experts, physicians and patient representatives convened by NYU, the purpose of CompAC, a pilot program, is to ensure a fair, objective and ethical evaluation of single patient requests for investigational medicines. Having seen the success of the pilot, Johnson and Johnson is excited to implement across their portfolio for relevant assets. Companies, patient advocates, institutional review boards, and government officials have expressed interest in extending the CompAC model to other agents and settings.

EUROPEAN FINALIST

UCB: Spanish Health Ecosystem Solution Project

more info watch video

The Spanish Health Ecosystem Solution Project has been developed with an aim of evolving from treating patients to taking care of people, designing and implementing patient solutions that truly impact their lives.

UCB Pharma manufactures and commercializes Cimzia, an Anti-TNF indicated for Rheumatoid Arthritis, Spondiloarthritis and Psoriasic Arthritis, in Europe.

The objective with the Health Ecosystem Project is to link our Risk Sharing Agreements with a Patient Support Program to maximize the Cimzia patient experience during these first 12 weeks of onboarding, the most critical stage for new treatment for patients.

NORTH AMERICAN FINALIST

Abbott India: Vertigo Exercise Mobile App

more info watch video

Patient Education 3d HD 360 degree app for better treatment outcome with patients of Vertigo: Empowering HCP to ensure patience adherence and better outcomes

EUROPEAN FINALIST

Daiichi Sankyo Europe GmbH: Adherence Package

more info watch video

More information coming soon…

NORTH AMERICAN FINALIST

United Therapeutics Oncology: The Skivolo Project

more info

For children with neuroblastoma and those who care for them, the treatment journey can be long and confusing, full of hospitalizations, procedures, and drugs, even a new language. Parents need basic information. Kids just need a friend who understands what they’re going through. Working with oncology nurses, educators, and health literacy experts, we created informational materials that were easier to understand, and more important, designed to be shared between parents and kids: The Skivolo Project. The Skivolo project is a groundbreaking series of informational children’s books and digital projects that have filled a crucial need for hospitals and cancer centers, and are being translated into 5 languages.

COMMENDED
EUROPEAN FINALIST

AbbVie: Doctors Channel YouTube

more info watch video

Complex Medical Information is made Easy & Accessible by AbbVie's 'Doctors Channel on YouTube'. It provides educational health videos on a wide variety of medical conditions & diseases-directly from the experts. Senior physicians voluntarily joined the initiative to create short, simple and clear videos that explain symptoms, disease progression, treatment methods and provide links to further information. Hundreds of thousands of surfers have already obtained objective and reliable answers, information & directions prior to an office visit, saving valuable time during the actual doctor’s appointment.

NORTH AMERICAN FINALIST

Abbott India: Wifi Thyroid Clinics

more info watch video

Abbott has always been in the forefront of initiatives to spread awareness about thyroid disorders, improve access to diagnosis and help millions of Indians lead a better life. Wifi Thyroid Clinics” – Is an Effective and Measurable way for Patient awareness on thyroid disorders inside the doctor’s clinic. This initiative has helped convert “waiting time” in doctor’s chamber to “awareness building time” using internet less wifi technology and further helped Abbott India to move a step closer in their vision of Making India Thyroid Aware. The initiative was launched in 252 Endocrinologists clinics. The objective of launching at Endocrinologist clinics has been high inclinic waiting time and Endos getting large pool of patients with high risk of thyroid disorders. The initiative was launched during World Thyroid Day in the month of May and has reached out to 85000 patients in 6 month’s time with 330 view/download rate per clinic.

NORTH AMERICAN FINALIST

UCB: Right Start Nurse Program

more info watch video

For most patients, living with and self-managing a chronic condition requires a fair amount of knowledge, gentle care and, most of all, strong support. Now in its expansion phase, UCB’s CIMplicity® Right Start Nurse Program is a free, educational resource that provides exactly what new CIMZIA® patients need—with the right information, delivered at just the right time throughout their journey. Initially, 300-400 CIMZIA patients registered monthly, which has increased to 500+ monthly. Since inception, more than 45K calls were successfully made. Overall, the program received a 99% satisfaction rate, with Net Promoter Scores (NPS) of 67% likely to recommend the program and 54% likely to recommend speaking to a doctor about CIMZIA.

Most Valuable Pharma Collaboration

The finalists of this award are either a pharma-pharma or pharma-non-pharma initiative which clearly brings a new proposition to customers and/or healthcare systems, creates new value and redefines what is possible in our industry with a degree of lateral thinking.

EUROPEAN FINALIST

AbbVie: What happens when patients meet young talented designers

more info watch video

This project was based on the Pharma 3.0 business model- partnering with non-traditional partners to improve health-related outcomes, using an holistic approach. This pioneering innovative project was initiated following AbbVie’s patient centric approach. Following findings from patient journeys, interviews with HCP & Patients, market research and more, we gather lot observations and develop insights about the daily life struggles of the patients. AbbVie collaborate together with relevant partners as- Bezalel (Academy of arts & design), Patient Association Groups, HCPs, to develop innovative tailored solutions to address RA patients’ & Parkinson patients' unmet needs , in order to create a remarkable impact on their lives.

NORTH AMERICAN FINALIST

phactMI

more info watch video

phactMI™ is a collaboration of pharmaceutical company Medical Information (MI) departments that are dedicated to supporting healthcare professionals in their commitment to provide quality patient care.

At phactMI, we understand that healthcare professionals have a wide range of medical information needs, and we are supportive of the spectrum of drug information providers. phactMI.org is a unique portal that provides easy access the resources of Medical Information departments of phactMI member companies.

phactMI.org can help you access current, accurate, and scientific information, about drug interactions, stability/compatibility, and dosage and administration – sometimes including access to unpublished information that may not be available from our member pharmaceutical organizations.

WINNER
EUROPEAN FINALIST

AbbVie: Doctors Channel YouTube

more info watch video

Complex Medical Information is made Easy & Accessible by 'Doctors Channel on YouTube'. It provides educational health videos on a wide variety of medical conditions & diseases-directly from the experts. Senior physicians voluntarily joined the initiative to create short, simple and clear videos that explain symptoms, disease progression, treatment methods and provide links to further information. AbbVie’s vision and foresight underpins this major step toward answering patients' needs by bringing to life this online “go-to” resource. Thanks to the participation of major stakeholders, patients know they are accessing the best information available online.

NORTH AMERICAN FINALIST

The Critical Path Institute

more info

Critical Path Institute (C-Path), founded in 2005 in Tucson, Arizona, is an independent, nonprofit organization established with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the US Food and Drug Administration (FDA). C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established 12 global, public-private partnerships that currently include over 1,450 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. 

EUROPEAN FINALIST

LEO Innovation Lab with The Happiness Research Institute: PsoHappy

more info watch video

People living with psoriasis are up to 24% less happy than the average population. This is a significant gap and PsoHappy, the first happiness index for people living with psoriasis, is committed to documenting and addressing the well-being inequalities psoriasis creates.

PsoHappy will continue to document the levels of happiness and explore what makes good living for people with psoriasis, while also expanding the successful approach to other skin and chronic disease areas. Our aim is to build a coherent, strong strategy around happiness that can unite all the relevant stakeholders and people living with psoriasis in one strong voice.

NORTH AMERICAN FINALIST

"Inspiring Hope" Ideathon

more info watch video

Innovation through Collaboration: INC Research and the Center for Information and Study on Clinical Research Participation (CISCRP) worked in partnership to develop the "Inspiring Hope" Ideathon, a new crowdsolving competition designed to generate unique and effective ideas that raise awareness of clinical trials and study participation.

This ground breaking event, held on September 27-28, 2016 at District Hall in Boston, brought together industry leaders and patients along with advocacy groups and other stakeholders from multiple industries to address:

  • raising public awareness about the role that clinical research plays in our society
  • building more momentum to increase personal, long-term and ongoing participation in clinical studies
  • stimulating more active engagement within the clinical research community, particularly those who seek alternative health care options
  • creating higher levels of recognition and appreciation for clinical trial volunteers

In a competition that inspired nearly 70 entries from around the world, 14 ideas were then shortlisted for their potential to help address the critical need to increase awareness of clinical trial participation among patients, healthcare professionals and the general public.

As a result of the live competition and a tremendous amount of momentum, the winning team, in collaboration with INC Research and CISCRP, now focuses on progressing the idea into a viable solution. Since the event, INC and CISCRP have held a kick off meeting with the winning team, which has already started making their idea a reality. Subsequent progress meetings are planned for the remainder of this year and updates will be presented at patient-focused events throughout next year.

EUROPEAN FINALIST

Novartis: Europe Patient Innovation Summit

more info watch video

The European Patient Innovation Summit brought together over 130 patient advocacy groups from across 22 European countries to discuss how technology is revolutionizing life for patients and patient groups alike. With 8 different disease communities represented (ankylosing spondylitis, asthma, heart failure, migraine, multiple sclerosis, psoriasis and psoriatic arthritis, rare autoinflammatory diseases; retina) the Summit created a platform for knowledge exchange and best practice sharing through an innovative mix of presentations, panel discussion and Q&A sessions, workshops, and disease-community forums. The momentum gained during the meeting is being maintained and plans for the next event are already well under way.

NORTH AMERICAN FINALIST

The Clinical Study Data Request Consortium

more info watch video

Very often, patient level data are isolated and scattered among research sponsors, seldom being shared. Because of this, clinical research, with all its challenges, is often duplicated and can potentially miss signals that may only become clear when data pools are combined. The Clinical Study Data Request (www.clinicalstudydatarequest.com) launched in 2014, now has 13 member companies who represent a consortium of industry leaders in the data sharing community. Through a common mission, they are inspired to drive value for patients through scientific and medical innovation by facilitating the responsible sharing of patient-level data from clinical studies.

The aim is to realize a broad, independent solution to allow access to data from clinical studies conducted by multiple companies and organisations, encouraging openness and transparency. The members of ClinicalStudyDataRequest.com set the bar for themselves to be the researcher-preferred platform for accessing high-quality patient-level data. This consortium offers researchers the most vast and broadest therapeutic variety of any data access platforms currently available. While doing so, they also uniquely balance the priority of data access and data utility with industry-leading principles and practices to ensure protection of patient privacy, scientific merit, and maintain a focus on patient value in the resulting researcher.

In alignment with the five guiding principles established by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) for the responsible sharing of clinical study data, the member companies have committed to the following: enhancing data sharing with researchers; enhancing public access to clinical study information; sharing results with patients who participate in clinical studies; certifying procedures for sharing clinical study information; and reaffirming commitments to publish clinical study results.

To that end, ClinicalStudyDataRequest.com has put real energy and careful thought into meeting the challenges of protecting patient confidentiality, applying the practicalities of anonymizing data and sharing data via secure access systems, and by design of their independent review process, ensuring that data is used for valid scientific verification or innovation, by qualified research teams, with potential benefit to patients. The site is the broadest one of its kind, with the highest sponsor commitment—including an independent review panel (managed by The Wellcome Trust) to ensure trust and accuracy.

EUROPEAN FINALIST

aparito: mHealth to capture meaningful patient outcomes in rare diseases

more info watch video

With the continuing pressures on NHS resources, clinicians time and increased costs on transportation, the ability to remotely monitor a patient with a progressive disease is a distinct advantage. Patients would not have to struggle to get to the hospital unless absolutely required and the consultant can review data from the APP and the wearable in an environment with less time constraints than at a patient appointment. The consultant can also be more aware of the progression of the disease by evaluating the data before a patient attends clinic therefore ensuring time at the clinic is not wasted. From the pharma industry perspective, accurate recording of patient progression on treatment can enable clinicians to gauge the benefits of the treatment and report findings appropriately in peer reviewed journals or international symposia.

NORTH AMERICAN FINALIST

Takeda Oncology, Multiple Myeloma Research Foundation and CURE Media Group: Moving Mountains for Multiple Myeloma Team

more info watch video

Moving Mountains for Multiple Myeloma is a collaboration between CURE Media Group, Takeda Oncology and the Multiple Myeloma Research Foundation (MMRF) to raise awareness and funds for multiple myeloma research. Multiple myeloma is an incurable blood cancer that gives patients less than a 50 percent chance of survival beyond five years, according to the National Cancer Institute. The program, launched in September 2015, brings together multiple myeloma patients, family members, doctors and supporters to raise funds, inspire hope and spread awareness of the disease. Since its launch, Moving Mountains for Multiple Myeloma has led teams of fearless climbers on hikes to Mount Kilimanjaro, the Grand Canyon and Machu Picchu. To date, the program has raised a total of nearly $500,000 for multiple myeloma research.

EUROPEAN FINALIST

The Synergist: Patient Focused Medicines Development Initiative

more info watch video

Medicines are developed to improve the lives of patients. Serving patients in the best way possible requires a deep understanding of their needs and priorities, which can be gained only through direct, sustained and constructive interactions with patients. Health stakeholders agree that broadening patient engagement is key to improving drug development and providing solutions that achieve both clinical and patient-desired outcomes. What is needed now is a consistent approach to patient engagement, through development and implementation of an efficient, measurable and reliable meta-framework that involves patients as partners. By partnering with patients to design and develop new solutions, we can co-create methods to help them achieve and maintain their health goals. The Patient Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition whose activities are funded by member organisations. It is an open non-profit partnership based on expertise and commitment toward better and meaningful patient engagement inside and outside of member organisations.

NORTH AMERICAN FINALIST

Bayer & the Hemophilia Advocacy Advisors Board: A Model of Authentic Partnership

more info watch video

While patient advocates have long been an important part of the medical landscape, manufacturers have traditionally distanced themselves from engaging with these crucial stakeholders. Bayer was keen to shift this phenomenon and create an authentic engagement opportunity with the world’s most recognized patient advocates, so together they could identify and tackle the most critical issues and concerns faced by those living with hemophilia. The challenge was to do so in a credible way that protected the patient and was not perceived as being self-serving. It was also essential that this activity was supportable from a business perspective, while delivering tangible results.

And the results have been exceptional; with the creation of Hemophilia Excellence by Bayer, a comprehensive portfolio of support programs and resources for patients, caregivers and healthcare professionals, and the establishment of the Hemophilia Advocacy Advisors Board (HAAB), an advisory body comprised of top patient advocates from across the globe, this partnership is set to address the unmet needs in the bleeding disorders community.

Unique in the industry, this partnership is raising the standard of care across the globe and is a superb example of how authentic engagement can exist – and thrive – despite today’s complex healthcare environment. The HAAB provides expert guidance and support to help the hemophilia community advocate for itself in this rapidly changing environment, while keeping a close eye on the healthcare landscape to ensure that the standard of care is continually addressed. One of the most notable outputs of this partnership is the annual Global Haemophilia Advocacy Leadership Summit, which completed its fifth year in January in Amsterdam, The Netherlands. The Summit is a platform where advocates from around the world can identify and focus on issues affecting them and take part in trainings to implement change within their hemophilia communities.

Following a think tank model has fostered a true dialogue between the hemophilia community and its industry partners that elevates collaboration to a new level, while making a real difference in patients’ lives.

Most Valuable HCP or Healthcare Initiative

The finalists of this award are innovative projects designed to deliver tangible working and healthcare improvements both in the long and short term. Demonstrating understanding of real health requirements prior to implementation, these winning projects have been managed to an outstanding level and have made an exceptionally positive impact on their intended customer.

EUROPEAN FINALIST

Takeda: In Their Shoes

more info watch video

Campaign mission: Create a corporate communications programme that goes beyond traditional methods to transport employees into the patient world, increasing their understanding of patient lives.

NORTH AMERICAN FINALIST

Eli Lilly with VMS BioMarketing: The Safe Injection Training Program

more info watch video

The Safe Injection Training Program developed by Eli Lilly and Company and executed in conjunction with VMS BioMarketing was designed to significantly enhance the quality of education for HCPs caring for people with diabetes in a variety of institutional settings, large or small, whether they are transitioning between injection methods, piloting new methods, or training discharge staff to help patients self-manage their diabetes. Through partnering with facilities, anywhere from 10 to several thousand patient care staff—RNs, LPNs, PAs, MAs, RPhs, and PharmDs—are trained by a Lilly-contracted Nurse Educator to properly use a vial/syringe or a Lilly prefilled insulin pen for inpatient therapy or to prepare patients for discharge. Programs are presented in a variety of care settings including hospitals, long-term care facilities, pharmacies, or healthcare systems.

Whether they are administering insulin by vial and syringe or by an insulin pen, even veteran HCPs may benefit from training in best practices for insulin injection, the latest guidelines for storage, and current information on safety issues. Since 2008, over 100,000 HCPs have been trained. In a formal survey of customers, 98% felt the information learned in the program will improve safety practices for syringe or pen use at the facility.

EUROPEAN FINALIST

UCB: China HCP-Facing WeChat Project

more info watch video

In China, the traditional communication between HCPs and Pharma are brief face-to-face visits or meetings which result in low effectiveness (time consuming and high cost for transportation) and generalized content that is not tailored to HCPs’ needs.

UCB sought to facilitate higher effectiveness, as well as more immediate and audience-centric communication, for millions of HCPs in China via a free app platform that enabled HCPs to learn more about UCB solutions in related therapeutic areas. WeChat is an instant messaging service developed in 2011 by Tencent in China, and is now a leading social media platform and “go-to” information resource. It is one of the largest standalone messaging apps by monthly active users, with over a billion created accounts, 700 million active users—and more than 70 million outside of China. Meanwhile, on average, HCPs spent 23.7 hours (2015 survey) on internet for information every week and more than 90% HCPs in big cities use WeChat frequently. To facilitate better communication between HCPs and Pharma, it made sense to use a popular, accessible platform such as WeChat which is a well adopted platform with no additional training required for immediate use.

NORTH AMERICAN FINALIST

Allergan with Complete HealthVizion: IBSCounSEL.com

more info watch video

IBS affects approximately 11% of the world’s population – 35 million people in the US alone! It has a drastic physical and emotional impact; 38% of those in the tertiary setting have contemplated suicide. Despite being one of the most commonly encountered disorders in primary care and gastroenterology, IBS has historically been viewed as benign, often disregarded as unimportant or not a legitimate disease. Internet searches of “IBS” yield over 42 million websites but these vary in quality and accuracy, and all share a lack of clear, clinically implementable information that healthcare professionals (HCPs) can trust. Consequently, many HCPs remain poorly informed; their misconceptions and lack of awareness can leave patients feeling stigmatized and suffering for years without a formal diagnosis or symptom relief.

With a firm commitment to improve the lives of people living with IBS, Allergan and Complete HealthVizion established a multidisciplinary expert group of gastroenterologists, primary care physicians, nurse practitioners, physician assistants, and patient advocates – The IBS CounSEL. Its mission is to provide Support, Education, and Leadership to achieve excellence in the care of people with IBS. This is the first and, to date, only multidisciplinary HCP group of its kind dedicated to improving IBS care.

A disease-awareness program was initiated to provide compelling and clinically relevant information to positively change HCP behaviors and improve the understanding, diagnosis, and management of IBS in day-to-day practice – IBSCounSEL.com was born! To date, IBSCounSEL.com has been accessed over 1500 times by over 900 unique visitors.

EUROPEAN FINALIST

GlaxoSmithKline with Vertic: Singapore Asthma 90 Second Speed Course

more info

Only 18% of Singapore asthma patients are controlled, while 56% of doctors believe them to be controlled.

Our task was to get this important message across to HCPs at Singapore polyclinics and provide them with the tools to uncover their patients’ lack of control. This audience is extremely time-poor and has less affinity with their patients compared to GPs or specialists who see the same patient regularly.

We needed to fit in with the HCP’s busy lives, convey the facts and tell the patients’ story in an interesting, compelling manner.

To differentiate ourselves from the usual long-form educational content HCPs are exposed to, we built our solution around brevity – making its low time-impact a key selling point. We developed the Singapore Asthma 90 Second Speed Course, a course delivered to HCP’s smartphones via a link sent by SMS during their morning commute (Singapore is a market where the use of public transport is prevalent at all levels of society).

NORTH AMERICAN FINALIST

Abbott India: In-clinic Scientific Detailing in Virtual Reality

more info watch video

VIRTUAL REALITY APP – GOOGLE CARDBOARD: Frugal innovation for immersive, differentiated experience (First in Industry Virtual Reality experience for scientific detailing to HCP via all medical reps)

WINNER
EUROPEAN FINALIST

Boehringer Ingelheim: The Angels Initiative

more info watch video

Every 30 minutes a stroke patient that could have been saved dies or is left permanently disabled because they are treated in the wrong hospital. In fact only about 1/3 stroke patients in Europe have access to organised stroke care.

The Angels Initiative was designed to change that by focussing on two clearly defined goals:

  1. We need to establish MORE stroke ready hospitals.
  2. We need to help all existing stroke centres and stroke ready hospitals get BETTER at treating acute stroke patients.

Our aim is to save 100,000 lives by creating a community of 1,500 stroke ready hospitals all working together every day to improve their stroke care. We aim to achieve this by May 2019.

NORTH AMERICAN FINALIST

Shire with Snow Companies: Patient Ambassador Stories to HCP Audiences

more info

Including Patient Ambassador Stories in HCP Audience programs is a novel way to raise awareness of Binge Eating Disorder (B.E.D.) in the healthcare community. Patient Stories bring a face and a name to the disorder and show the real impact B.E.D. has on everyday lives. Stories encourage open communication between healthcare professionals and patients which can help identify patients and lead to higher diagnosis rates. By incorporating stories, companies can bring about positive and meaningful change in the healthcare industry and further educate and assist the community in awareness, recognition, and adoption.

EUROPEAN FINALIST

Novartis with Boomerang: ViaOpta Simulator

more info watch video

Over a quarter billion visually impaired patients are treated each year. Until now physicians have not been able to truly visualize the real world implications these patients face.

Better treatment begins with better understanding - Not only the physical, but also the emotional frustration of the patient.

With the ViaOpta Simulator app physicians can view life through the lens of a patient.

Virtually replicated syndromes and corresponding scientific descriptions come together to form a portable augmented reality experience. Bringing physicians and patients closer together by allowing the physicians to walk in the patients shoes and continue a dialog that treats beyond the conventional pill.

ViaOpta Vision simulator app - Designed specifically for healthcare professionals, your first person look at living with a visual impairment.

EUROPEAN FINALIST

Lundbeck with Complete HealthVizion: ReTHINCing the role of cognition in depression

more info watch video

More information coming soon…

Customer Innovator Award

The finalists of this award is a person or team who have determined the needs of their customer, and created a relevant approach irrespective of traditional methods. They have an exceptional aptitude for having or sourcing innovative ideas as well as executing them effectively. The finalists exhibit the qualities of a true innovator, who strives for patient value, influences others and provides useful learning and examples for others in the industry.

Finalist Headshot
EUROPEAN FINALIST

Bridha Sridhar, UCB, DRIVE™ Parkinson's Disease Treatment Drivers

more info watch video

Due to a high level of uncertainty with their medications, patients with Parkinson’s Disease often make ambiguous trade-offs. Switching to other treatment choices results in a 40-50% drop-off rate after first month of treatment up through the third month – but why, and what are the triggers? Lack of any objective measure means subjective feelings heavily moderate decision making.

To address the real patient needs, we sought research methodologies that go beyond focus groups and interviews, which mostly deal with the conscious and rational responses. Innovative approaches that are designed to minimize bias in research settings were deployed.

The UCB DRIVETM PD Research team is a cross-practice, cross-region and cross-mission initiative aimed at understanding subconscious drivers in the Parkinson’s patient journey, starting with the premise that around 80% of drivers are subconscious.

Finalist Headshot
NORTH AMERICAN FINALIST

Akshat Aiyer, Abbott India

more info watch video

More information coming soon…

Finalist Headshot
WINNER
EUROPEAN FINALIST

Kristian Hart-Hansen, LEO Innovation Lab, LEO Pharma

more info watch video

LEO Innovation Lab is one of a kind, ambitious initiative designed to improve the lives of people living with skin conditions by adopting user-centric principles and disrupting the usual approaches of pharma.

In less than 18 months since he established the Lab, Kristian Hart-Hansen, its co-founder and CEO, has championed more than 35 concepts and prototypes, out of which 8 are already available to patients in UK, Canada and Denmark. He has built a multi-disciplinary team of 40 designers, software engineers, business specialists, growth hackers, anthropologists that are using agile development principles to develop and launch at pace solutions that are underpinned by technology and data to improve the lives of living with skin conditions.

Finalist Headshot
NORTH AMERICAN FINALIST

Kathy Cole, PMG Research

more info watch video

With time and costs continuing to be systemic, unstainable issues for our industry as a whole, Kathy Cole made a decision to leverage her knowledge, expertise and passion to do her part in reversing the trend. Her leadership in developing what is proving to be a high value process, Data-Driven Feasibility leads to predictable outcomes and has impacted the PMG business in a short period of time with expected long-term value to increase exponentially. Applied to the larger site enterprise and industry, it is plausible to expect a significant paradigm shift in the years ahead that reduces time and cost simply through effective and reliable analysis used to ensure the right trials are placed at the right sites with the right providers.

Finalist Headshot
EUROPEAN FINALIST

David Aubert, Psoriasis treatment beyond the pill, Philips BlueControl

more info watch video

New blue light therapy with Philips BlueControl – a big step for psoriasis treatment and patients’ lives.

Convenience is a key factor when consumers all over the world choose services, products and suppliers. This trend also affects the medical world. In particular, patients with chronic diseases are looking for treatments that interfere less with their everyday lives and make them feel less like a patient.

International studies conclude that 75% of psoriasis patients are dissatisfied with their treatment. The frequent application of ointments is perceived to be inconvenient and time-consuming, limiting patients in their daily activities. The treatment compliance is low.

The need for a new treatment paradigm taking the practical and emotional impact the treatment poses on the patients more into account is obvious. In other words, treatments need a “usability upgrade” – it needs to be easier to integrate treatments into the patients’ daily lives and reduce the worries about side effects.

With the introduction of the blue light phototherapy device Philips BlueControl, we have proven that treatments that are gentle, convenient and effective noticeably improve the compliance rate. Our recent clinical study concludes that 98% of patients were compliant in following the blue light treatment recommendations over the trial period of four months.

As Philips BlueControl is effective by using visible blue light only, no UV radiation risks are associated. Philips BlueControl is the world’s first wearable UV-free blue LED light medical device to treat plaque psoriasis at home.

Finalist Headshot
NORTH AMERICAN FINALIST

Peter Stueckemann, UCB

more info

The CIMplicity® Home Health Program, launched in 2008, is the only one in its category that offers in-home support. It is also the only patient-centered program in its category that can quantify patient value: A 10% greater drug persistency over eight years; 20% greater compliance, also sustained over eight years; 50% fewer hospitalizations; and subsequently reduced payer costs of $4k-$10k per patient. Since the program’s inception, CIMZIA has consistently held a net promoter score of 67—unprecedented for a drug in the Crohn’s disease category.

Finalist Headshot
NORTH AMERICAN FINALIST

Nicki Norris, Symphony Clinical Research

more info watch video

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Christine Grogan, Acelity

more info

More information coming soon…

Lifetime Achievement Award

Finalist Headshot
EUROPEAN FINALIST

Professor Richard Barker, Director, CASMI

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Len Schleiffer, Chief Executive, Regeneron

more info

Leonard S. Schleifer, MD, PhD, founded Regeneron in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a Director and its President and Chief Executive Officer since its inception and acted as Chairman of the Board from 1990 through 1994. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.

Here a 3 minute clip about Len’s motivation for leading Regeneron here https://www.regeneron.com/leadership

Here is a video of Len explaining why the pharma industry doesn’t actually put patient’s first http://video.cnbc.com/gallery/?video=3000582820

Finalist Headshot
WINNER
EUROPEAN FINALIST

Richard Bergström, Director-General, EFPIA

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Freda Lewis-Hall, CMO, Pfizer

more info

As Pfizer's Chief Medical Officer, Freda Lewis-Hall leads Pfizer Medical, the division of the company responsible for the safe, effective and appropriate use of Pfizer medicines and vaccines around the world. Before joining Pfizer in 2009, Freda held senior leadership positions in medical affairs and new product development with Vertex, Bristol-Myers Squibb, Pharmacia and Lilly. Prior to joining the biopharmaceutical industry, she served as vice chairperson and associate professor of the Department of Psychiatry at Howard University College of Medicine and was an advisor to the National Institute of Mental Health. Trained as a psychiatrist, Freda launched her medical career in frontline patient care and became well known for her work on the effects of mental illness on families and communities, and on issues of health care disparities. She is a Distinguished Fellow of the American Psychiatric Association.

In 2010, Freda was appointed by the Obama Administration to the inaugural Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI), and in 2012 she was appointed chair of the Cures Acceleration Network Review Board and a member of the National Center for Advancing Translational Sciences (NCATS) Advisory Council of the National Institutes of Health. She also serves on the Executive Committee of the Clinical Trials Transformation Initiative and on numerous other boards, including those of Harvard Medical School, Save the Children, Tenet Healthcare Corporation, and The Institute of Medicine’s Forum on Drug Discovery, Development, and Translation.

She shares health and medical information at GetHealthyStayHealthy.com

Here is Freda talking at TEDMED https://youtu.be/wY8I-2rDgNE

Finalist Headshot
EUROPEAN FINALIST

Dr Dominique Limet, CEO, ViiV Healthcare

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Ken Getz, CISCRP & Tufts

more info

Kenneth A. Getz is the Founder and Chairman of The Center for Information and Study on Clinical Research Participation (CISCRP), a nonprofit organization that he created to educate and raise public awareness of the clinical research enterprise, the Director of Sponsored Research Programs and an Associate Professor at the Center for the Study of Drug Development, Tufts University School of Medicine, where he studies R&D management and operating models, investigative site, outsourcing, and study volunteer trends and policies. Ken is also the Founder and former owner of CenterWatch, a trusted online source for detailed information about active clinical trials that can be accessed by patients and their advocates.

Mr. Getz is well known and highly respected throughout the pharmaceutical, research, and academic industries and has extensive experience measuring public and patient attitudes, perceptions, and experiences with all aspects of the clinical research process. He has worked tirelessly to find new and better ways to improve patient experiences with clinical research and transform public perception about clinical trial participation.

Mr. Getz is also a distinguished speaker at conferences, symposia, universities, and corporations, and has published more than 200 articles and chapters in peer-review journals, books, and in the trade press. He is the author of two nationally recognized books for patients, their families, and advocates titled, “Informed Consent: A Guide to the Risks and Benefits of Volunteering for Clinical Trials” and “The Gift of Participation.” Mr. Getz has also been the recipient of several awards for innovation and scholarship, such as the 2006 “Innovator in Clinical Research” award from the Association of Clinical Research Professionals (ACRP), a 2011 Lifetime Achievement award from the Institute of International Research, and a 2015 DIA Fellow inductee. Mr. Getz has held a number of board appointments in the private and public sectors, including serving on the Institute of Medicine’s Clinical Research Roundtable, the DIA Foundation, ACRP's Future Trends Committee, the Board of Directors of the DIA Foundation, the Consortium to Examine Clinical Research Ethicist Johns Hopkins, and the Clinical Trials Transformation Initiative (CTTI).

In 2007, Mr. Getz was named was named one of the 100 most inspiring individuals in the life sciences. Most recently, Mr. Getz and CISCRP, joined forces with INC Research to hold the first ever “Inspiring Hope” Ideathon, where more than 70 ideas where submitted for a crowd-sourcing competition to find new, innovative solutions for increasing clinical research awareness.

Finalist Headshot
EUROPEAN FINALIST

Sir Andrew Witty, CEO, GlaxoSmithKline

more info

More information coming soon…

Finalist Headshot
NORTH AMERICAN FINALIST

Joaquin Duato, CEO, Johnson & Johnson Pharmaceuticals

more info

Joaquin Duato is a globally experienced, values-driven healthcare business leader and currently the Executive Vice President and Worldwide Chairman, Pharmaceuticals, at Johnson & Johnson, the world’s premiere healthcare company and fifth largest pharmaceutical business. He is a respected industry leader and is the Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). In recognition of his thought leadership, he was recently appointed to the Board of the CEO Roundtable on Cancer.

Joaquin played an instrumental role in leading the dramatic turnaround of the Johnson & Johnson pharmaceuticals business. A 27-year veteran of the Company, Joaquin was named Company Group Chairman of the Americas in 2009. He then continued leading the global transformation upon his appointment as Worldwide Chairman in 2011. With a proven track record of creating innovative commercial solutions and processes to support the Company’s cutting-edge medicines, he inspires employees to focus on transforming the lives of patients. The results are clear: with 16 new products launched since 2009 and 10 potential billion dollar medicines expected to be filed before 2019, the Johnson & Johnson pharmaceuticals sector is poised to remain one of the fastest growing top 10 pharmaceutical companies globally.

As a dual citizen of Spain and the US, Joaquin brings a unique international perspective to his work. With a career spanning three countries and two regions, he appreciates the value of diversity of experiences and perspectives. He brings this to bear externally as an active Board member of the US Spain Council and internally as the Executive Sponsor of the African American Leadership Council. His commitment to nurturing a culture of diversity was recognized in 2015 when he was named one of America’s Top 10 Hispanic Business Leaders by Hispanic Career World.

He is a champion of improving access to both health literacy and education more broadly through his role as Board member of the international charity Save the Children. He has served on the International Advisory Board of ESADE. Ultimately, Joaquin approaches every day with a clear sense of purpose and urgency, inspired by the words of Dr. Paul Janssen, “the patients are waiting.”

Joaquin speaking about how the industry needs to focus more on innovation https://www.youtube.com/watch?v=EStlI_-3ZR0

A huge thank you to all our judges who spent numerous hours assessing all of the entries - you can see our judges here